Institut Gustave Roussy-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Institut Gustave Roussy - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014039
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Institut Gustave Roussy (IGR) is a cancer research institute that offers healthcare services to patients suffering from cancer and conducts research to identify new therapies. The institute provides treatment for the diseases that include endocrine tumours, childhood cancer, gynecological cancers, brain tumours, gastrointestinal tumours, skin cancers, lung cancers, prostate cancers, bladder cancer, kidney cancer, oncogenetics, haematological cancers, sarcomas and complex tumours, and others. The institute also partners with Karolinska Institutet of Stockholm, Sweden; Uruguayan Ministry of Public Health; National Cancer Center of Tokyo, Japan; MD Anderson Cancer Center of Houston, the US; and others. IGR is headquartered in Villejuif, France.

Institut Gustave Roussy – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Institut Gustave Roussy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Institut Gustave Roussy, Medical Devices Deals, 2011 to YTD 2017 9
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
RXi Pharma and Gustave Roussy Enter into Research Agreement 11
Merus Enters into Co-Development Agreement with Institut Gustave Roussy 12
Enterome Bioscience Enters into Co-Development Agreement with Gustave Roussy 13
New Oncology Enters into Research Agreement with Gustave Roussy Cancer Campus 14
Gustave Roussy Enters into Research Agreement with AstraZeneca 15
Ipsen Enters Into Co-Development Agreement With Institut Gustave Roussy 16
Licensing Agreements 17
Therapeutic Solutions International Enters into Licensing Agreement with Gustave Roussy 17
Institut Gustave Roussy – Key Competitors 18
Institut Gustave Roussy – Key Employees 19
Institut Gustave Roussy – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Key Facts 2
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Institut Gustave Roussy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Institut Gustave Roussy, Deals By Therapy Area, 2011 to YTD 2017 8
Institut Gustave Roussy, Medical Devices Deals, 2011 to YTD 2017 9
Institut Gustave Roussy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
RXi Pharma and Gustave Roussy Enter into Research Agreement 11
Merus Enters into Co-Development Agreement with Institut Gustave Roussy 12
Enterome Bioscience Enters into Co-Development Agreement with Gustave Roussy 13
New Oncology Enters into Research Agreement with Gustave Roussy Cancer Campus 14
Gustave Roussy Enters into Research Agreement with AstraZeneca 15
Ipsen Enters Into Co-Development Agreement With Institut Gustave Roussy 16
Therapeutic Solutions International Enters into Licensing Agreement with Gustave Roussy 17
Institut Gustave Roussy, Key Competitors 18
Institut Gustave Roussy, Key Employees 19
Institut Gustave Roussy, Subsidiaries 20

★海外企業調査レポート[Institut Gustave Roussy-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Copperbelt Energy Corporation Plc (CEC):電力:M&Aディール及び事業提携情報
    Summary Copperbelt Energy Corporation PLC (CEC) is an electric utility that generates, transmits, distributes and sells energy. The company generates electricity from hydro, solar, gas and thermal sources; transmits electricity through a network of transmission lines and high voltage substations and …
  • Hong Leong Group:企業の戦略・SWOT・財務情報
    Hong Leong Group - Strategy, SWOT and Corporate Finance Report Summary Hong Leong Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Republic National Distributing Co:企業の戦略・SWOT・財務情報
    Republic National Distributing Co - Strategy, SWOT and Corporate Finance Report Summary Republic National Distributing Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Schreiber Foods Inc:企業の戦略的SWOT分析
    Schreiber Foods Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Energy Development Corp (EDC):電力:M&Aディール及び事業提携情報
    Summary Energy Development Corp (EDC), formerly Philippine National Oil Company, is a diversified renewable energy company. The company explores, develops, operates and utilizes geothermal energy and other indigenous renewable energy projects in the Philippines. EDC by utilizing geothermal energy an …
  • Bicycle Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Bicycle Therapeutics Ltd (Bicycle Therapeutics) is a biotechnology company that develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company's proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to ide …
  • Bank Sepah:企業の戦略・SWOT・財務情報
    Bank Sepah - Strategy, SWOT and Corporate Finance Report Summary Bank Sepah - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Helen of Troy Ltd:企業の戦略・SWOT・財務情報
    Helen of Troy Ltd - Strategy, SWOT and Corporate Finance Report Summary Helen of Troy Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sumitomo Mitsui Trust Holdings Inc
    Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Izocam Tic Ve San AS:企業の戦略・SWOT・財務情報
    Izocam Tic Ve San AS - Strategy, SWOT and Corporate Finance Report Summary Izocam Tic Ve San AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • China CITIC Bank Corporation Limited:企業の戦略・SWOT・財務情報
    China CITIC Bank Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China CITIC Bank Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Kawasaki Heavy Industries, Ltd.:企業の戦略・SWOT・財務分析
    Kawasaki Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kawasaki Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Sacmi Imola S.C. :企業の戦略・SWOT・財務情報
    Sacmi Imola S.C. - Strategy, SWOT and Corporate Finance Report Summary Sacmi Imola S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • High-Tech Grunderfonds Management GmbH:企業のM&A・事業提携・投資動向
    High-Tech Grunderfonds Management GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's High-Tech Grunderfonds Management GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Electricity Generating Public Co Ltd (EGCO):企業の財務・戦略的SWOT分析
    Electricity Generating Public Co Ltd (EGCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • National Cancer Center Hospital:製薬・医療:M&Aディール及び事業提携情報
    Summary National Cancer Center Hospital (NCC) is a healthcare service provider that offers cancer care services. The hospital provides cancer diagnosis and treatment services. It provides services such as examination, treatment, patient care services and co-medical support. NCC provides diagnosis an …
  • TEGNA Inc (TGNA):企業の財務・戦略的SWOT分析
    TEGNA Inc (TGNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • A&D Company Ltd (7745):企業の財務・戦略的SWOT分析
    Summary A&D Company Ltd (A&D Company) is a medical equipment company that manufactures, designs, develops, and distributes advanced measuring, controlling, monitoring, and testing instruments. The company’s products include powertrain testing systems, digital analog converter, DSP platform, model ba …
  • Kiadis Pharma NV (KDS):企業の財務・戦略的SWOT分析
    Summary Kiadis Pharma NV (Kiadis) is a biopharmaceutical company that develops and markets cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company offers cellular products including ATIR101 and ATIR201 for infusion. Its ATIR101 lowers the risks …
  • First Quantum Minerals Ltd:企業のM&A・事業提携・投資動向
    First Quantum Minerals Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's First Quantum Minerals Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆